Abstract:Commensal non-toxigenic Bacteroides fragilis confers powerful health benefits to the host, and has recently been identified as a promising probiotic candidate. We previously isolated B. fragilis strain ZY-312 and identified it as a novel strain based on 16S rRNA sequencing and morphological analyses. We also determined that ZY-312 displayed desirable probiotic properties, including tolerance to simulated digestive fluid, adherence, and in vitro safety. In this study, we aim to investigate whether ZY-312 meets the safety criteria required for probiotic bacteria through comprehensive and systematic evaluation. Consequently, the fatty acid profile, metabolite production, and biochemical activity of strain ZY-312 were found to closely resemble descriptions of B. fragilis in Bergey's manual. Taxonomic identification of strain ZY-312 based on whole genome sequencing indicated that ZY-312 and ATCC 25285 showed 99.99% similarity. The 33 putative virulence-associated factors identified in ZY-312 mainly encoded structural proteins and proteins with physiological activity, while the lack of bft indicated that ZY-312 was non-toxigenic. In vivo safety was proven in both normal and immune-deficient mice. The 11 identified antibiotic resistance genes were located on the chromosome rather than on a plasmid, ruling out the risk of plasmid-mediated transfer of antibiotic resistance. In vitro, ZY-312 showed resistance to cefepime, kanamycin, and streptomycin. Finally, and notably, ZY-312 exhibited high genetic stability after 100 passages in vitro. This study supplements the foundation work on the safety evaluation of ZY-312, and contributes to the development of the first probiotic representative from the dominant Bacteroidetes phylum.

A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health

Safety Evaluation of a Novel Strain of Bacteroides fragilis

Protective effects of Bacteroides fragilis against lipopolysaccharide-induced systemic inflammation and their potential functional genes

Therapeutic Potential of Bacteroides fragilis SNBF-1 as a Next-Generation Probiotic: In Vitro Efficacy in Lipid and Carbohydrate Metabolism and Antioxidant Activity

Investigations of Bacteroides spp. towards next-generation probiotics

Roles of intestinal bacteroides in human health and diseases

Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm

Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice

Next generation probiotics in disease amelioration

Gut Bacteroides species in health and disease

Vital Members in the Gut Microbiotas Altered by Two Probiotic Bifidobacterium Strains Against Liver Damage in Rats

Clostridium species as probiotics: potentials and challenges

Pathogenic Bacteroides fragilis strains can emerge from gut-resident commensals

Isolation, Detection, and Characterization of Enterotoxigenic Bacteroides fragilis in Clinical Samples

Next-Generation Probiotics: Microflora Intervention to Human Diseases

Pilot Safety Evaluation of a Novel Strain of Bacteroides ovatus

The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation

Next generation probiotics for human health: An emerging perspective

Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases

Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria